| Autor: |
Liu G; Department of Pharmacology, Cyclerion Therapeutics, Cambridge, Massachusetts., Shea CM; Department of Pharmacology, Cyclerion Therapeutics, Cambridge, Massachusetts., Jones JE; Department of Pharmacology, Cyclerion Therapeutics, Cambridge, Massachusetts., Price GM; Department of Medical Writing, Cyclerion Therapeutics, Cambridge, Massachusetts., Warren W; Department of Analytical Pharmacology, Ironwood Pharmaceuticals, Cambridge, Massachusetts., Lonie E; Department of Analytical Pharmacology, Ironwood Pharmaceuticals, Cambridge, Massachusetts., Yan S; Department of Discovery Informatics, Cyclerion Therapeutics, Cambridge, Massachusetts., Currie MG; Department of Research Management, Cyclerion Therapeutics, Cambridge, Massachusetts., Profy AT; Department of Development Management, Cyclerion Therapeutics, Cambridge, Massachusetts., Masferrer JL; Department of Pharmacology, Cyclerion Therapeutics, Cambridge, Massachusetts., Zimmer DP; Department of Pharmacology, Cyclerion Therapeutics, Cambridge, Massachusetts. |
| Abstrakt: |
Praliciguat, a clinical-stage soluble guanylate cyclase (sGC) stimulator, increases cGMP via the nitric oxide-sGC pathway. Praliciguat has been shown to be renoprotective in rodent models of hypertensive nephropathy and renal fibrosis. In the present study, praliciguat alone and in combination with enalapril attenuated proteinuria in the obese ZSF1 rat model of diabetic nephropathy. Praliciguat monotherapy did not affect hemodynamics. In contrast, enalapril monotherapy lowered blood pressure but did not attenuate proteinuria. Renal expression of genes in pathways involved in inflammation, fibrosis, oxidative stress, and kidney injury was lower in praliciguat-treated obese ZSF1 rats than in obese control rats; fasting glucose and cholesterol were also lower with praliciguat treatment. To gain insight into how tubular mechanisms might contribute to its pharmacological effects on the kidneys, we studied the effects of praliciguat on pathological processes and signaling pathways in cultured human primary renal proximal tubular epithelial cells (RPTCs). Praliciguat inhibited the expression of proinflammatory cytokines and secretion of monocyte chemoattractant protein-1 in tumor necrosis factor-α-challenged RPTCs. Praliciguat treatment also attenuated transforming growth factor-β-mediated apoptosis, changes to a mesenchyme-like cellular phenotype, and phosphorylation of SMAD3 in RPTCs. In conclusion, praliciguat improved proteinuria in the ZSF1 rat model of diabetic nephropathy, and its actions in human RPTCs suggest that tubular effects may contribute to its renal benefits, building upon strong evidence for the role of cGMP signaling in renal health. |
